Indication and Limitations of Use

Rayaldee® (calcifediol) extended-release 30 mcg capsules is indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Rayaldee is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.


This website is intended for US Healthcare Professionals

Secondary hyperparathyroidism (SHPT) due to chronic kidney disease (CKD) is a progressive disease that leads to significant morbidity and mortality

  • SHPT is associated with worse outcomes and significantly greater health care costs in patients with non-dialysis CKD, underscoring the need for SHPT management4
  • Affects 40% to 80% of patients with stage 3 or 4 CKD5

Associated with metabolic bone disease6

Associated with cardiovascular disease—the leading cause of mortality in patients with CKD7

Rayaldee has not been proven to reduce the risk of metabolic bone disease, calcification of CV and non-CV tissues, and CV disease.